Oncology
HBM contact: Dr Ivo Staijen, Dr Priyanka Belawat
Company status: public
Description - IO Biotech is a clinical stage biotech company developing disruptive
immune therapies for the treatment of cancer. Our pipeline of first-in-class
immune modulating anti-cancer therapies is based on a unique platform
technology enabling the activation of T cells that are specific for immune
inhibitory molecules.